Bone Biologics Co. (NASDAQ:BBLG – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 21,800 shares, an increase of 69.0% from the May 31st total of 12,900 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average daily volume of 79,700 shares, the short-interest ratio is currently 0.3 days.
Bone Biologics Stock Performance
NASDAQ BBLG traded up $0.02 during midday trading on Friday, hitting $1.23. The company had a trading volume of 30,827 shares, compared to its average volume of 100,682. The firm has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $2.59. Bone Biologics has a fifty-two week low of $1.13 and a fifty-two week high of $14.16.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.60) by $6.29. Equities research analysts forecast that Bone Biologics will post -5.32 EPS for the current year.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Recommended Stories
- Five stocks we like better than Bone Biologics
- How to Capture the Benefits of Dividend Increases
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What is the Australian Securities Exchange (ASX)
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.